EP Patent

EP1918291A1 — 3-Aminocarbonyl-substituted fused pyrazolo-derivatives as protein kinase modulators

Assigned to Novartis AG · Expires 2008-05-07 · 18y expired

What this patent protects

The present invention relates to pyrazolo[1,5-a]pyrimidine-3-carboxylic acid compounds of formula I or pharmaceutically acceptable salts thereof and their use for the treatment of protein kinase modulation responsive diseases.

USPTO Abstract

The present invention relates to pyrazolo[1,5-a]pyrimidine-3-carboxylic acid compounds of formula I or pharmaceutically acceptable salts thereof and their use for the treatment of protein kinase modulation responsive diseases.

Drugs covered by this patent

Patent Metadata

Patent number
EP1918291A1
Jurisdiction
EP
Classification
—
Expires
2008-05-07
Drug substance claim
No
Drug product claim
No
Assignee
Novartis AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.